Advances in Immunomodulating Therapy of HBV Infection

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2005 Jun 22

PMID 15968336

Citations 4

Authors

Chee-Kin Hui

George Kk Lau

Affiliations

Soon will be listed here.

Abstract

Patients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-alpha, lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers the only means of preventing the development of these complications. However, the efficacy of these agents, in terms of loss of Hepatitis B e antigen with or without seroconversion to Hepatitis B e antibody, normalization of serum alanine transaminase levels, loss of serum HBV DNA, and improvement in liver histology can only be achieved in 20-30% of those treated. Long-term treatment with either lamivudine or adefovir dipivoxil can result in the development of drug resistant mutants leading to an increased length of treatment with additional nucleoside analogues. These limitations of the current antiviral therapies underline the need for alternative therapies. Specific and nonspecific immunotherapeutic strategies to restore effective virus-specific T cell responses in those with chronic HBV infection offers an interesting alternative approach. These immunotherapeutic therapies include the adoptive transfer of HBV immunity, pegylated interferon and therapeutic vaccine therapies.

Citing Articles

Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.

Sherman A, Trehanpati N, Daucher M, Davey R, Masur H, Sarin S AIDS Res Hum Retroviruses. 2012; 29(4):665-72.

PMID: 23259453 PMC: 3607907. DOI: 10.1089/AID.2012.0320.

New muramyl dipeptide (MDP) mimics without the carbohydrate moiety as potential adjuvant candidates for a therapeutic hepatitis B vaccine (HBV).

Zhao N, Ma Y, Zhang S, Fang X, Liang Z, Liu G Bioorg Med Chem Lett. 2011; 21(14):4292-5.

PMID: 21683593 PMC: 7126364. DOI: 10.1016/j.bmcl.2011.05.056.

Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Le Hoa P, Huy N, Thu L, Nga C, Nakao K, Eguchi K Antimicrob Agents Chemother. 2009; 53(12):5134-40.

PMID: 19770281 PMC: 2786371. DOI: 10.1128/AAC.00276-09.

A novel model of acute liver injury in mice induced by T cell-mediated immune response to lactosylated bovine serum albumin.

Xu L, Zhao Y, Qin Y, Xu Q Clin Exp Immunol. 2006; 144(1):125-33.

PMID: 16542374 PMC: 1809629. DOI: 10.1111/j.1365-2249.2006.03034.x.

References

Mancini M, Hadchouel M, Tiollais P, Pourcel C, Michel M . Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg. J Med Virol. 1993; 39(1):67-74. DOI: 10.1002/jmv.1890390113. View

Celis E, Kung P, Chang T . Hepatitis B virus-reactive human T lymphocyte clones: antigen specificity and helper function for antibody synthesis. J Immunol. 1984; 132(3):1511-6. View

Cooksley W, Piratvisuth T, Lee S, Mahachai V, Chao Y, Tanwandee T . Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10(4):298-305. DOI: 10.1046/j.1365-2893.2003.00450.x. View

Livingston B, Crimi C, Ishioka G, Chisari F, Fikes J, Grey H . The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol. 1997; 159(3):1383-92. View

Davis H, Michel M, Whalen R . DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet. 1993; 2(11):1847-51. DOI: 10.1093/hmg/2.11.1847. View

Carreno V, Zeuzem S, Hopf U, Marcellin P, Cooksley W, Fevery J . A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol. 2000; 32(2):317-24. DOI: 10.1016/s0168-8278(00)80078-1. View

Shouval D, Adler R, Ilan Y . Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. Hepatology. 1993; 17(6):955-9. View

Yalcin K, Acar M, Degertekin H . Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection. 2003; 31(4):221-5. DOI: 10.1007/s15010-003-3187-1. View

Schulof R, Low T, Thurman G, Goldstein A . Thymosins and other hormones of the thymus gland. Prog Clin Biol Res. 1981; 58:191-215. View

10.

Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A . Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol. 2003; 98(11):2505-15. DOI: 10.1111/j.1572-0241.2003.07700.x. View

11.

Gu Y, Dahmen U, Doebel L, Li J, Dirsch O, Polywka S . Influence of CsA treatment on adoptive transfer of immunity after allogeneic kidney transplantation in rats. Transplant Proc. 2001; 33(1-2):398-400. DOI: 10.1016/s0041-1345(00)02064-9. View

12.

Lau G, Nanji A, Hou J, Fong D, Au W, Lin M . Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat. 2002; 9(4):280-7. DOI: 10.1046/j.1365-2893.2002.00361.x. View

13.

Wong D, Cheung A, ORourke K, Naylor C, Detsky A, Heathcote J . Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119(4):312-23. DOI: 10.7326/0003-4819-119-4-199308150-00011. View

14.

Rasi G, Mutchnick M, Di Virgilio D, Sinibaldi-Vallebona P, Pierimarchi P, Colella F . Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. J Viral Hepat. 1996; 3(4):191-6. DOI: 10.1111/j.1365-2893.1996.tb00094.x. View

15.

Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S . Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 1998; 102(5):968-75. PMC: 508962. DOI: 10.1172/JCI3731. View

16.

Ilan Y, Nagler A, Shouval D, Ackerstein A, Or R, Kapelushnik J . Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clin Exp Immunol. 1994; 97(2):299-302. PMC: 1534692. DOI: 10.1111/j.1365-2249.1994.tb06084.x. View

17.

Caselitz M, Link H, Hein R, Maschek H, Boker K, Poliwoda H . Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol. 1997; 27(3):572-7. DOI: 10.1016/s0168-8278(97)80363-7. View

18.

Lau G, Suri D, Liang R, Rigopoulou E, Thomas M, Mullerova I . Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology. 2002; 122(3):614-24. DOI: 10.1053/gast.2002.31887. View

19.

Gianotti N, Uberti-Foppa C, Boeri E, Marinelli M, Tambussi G, Finazzi R . Hepatitis B surface antigen clearance and appearance of antibodies against hepatitis B surface antigen after treatment with recombinant interleukin 2 in a human immunodeficiency virus-infected patient. Hepatology. 2001; 32(6):1409-10. DOI: 10.1053/jhep.2000.20150. View

20.

Sallberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K . Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther. 1998; 9(12):1719-29. DOI: 10.1089/hum.1998.9.12-1719. View